Detalhe da pesquisa
1.
The CLIP1-LTK fusion is an oncogenic driver in non-small-cell lung cancer.
Nature
; 600(7888): 319-323, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34819663
2.
DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy.
Mol Cancer
; 23(1): 97, 2024 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38730427
3.
Dexamethasone-sparing on days 2-4 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial).
Br J Cancer
; 130(2): 224-232, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37973958
4.
An approach for improvement of the accuracy of cancer gene panel testing.
Int J Clin Oncol
; 29(5): 571-581, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38472663
5.
Identification of risk factors for venous thromboembolism and validation of the Khorana score in patients with advanced lung cancer: based on the multicenter, prospective Rising-VTE/NEJ037 study data.
Int J Clin Oncol
; 28(1): 69-78, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36357710
6.
Atezolizumab for Pretreated Non-Small Cell Lung Cancer with Idiopathic Interstitial Pneumonia: Final Analysis of Phase II AMBITIOUS Study.
Oncologist
; 27(9): 720-e702, 2022 09 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35759340
7.
Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B).
Int J Clin Oncol
; 27(1): 112-120, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34643820
8.
Suitability of transbronchial brushing cytology specimens for next-generation sequencing in peripheral lung cancer.
Cancer Sci
; 112(1): 380-387, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-33124129
9.
Combining PD-L1 Expression and Standardized Uptake Values in FDG-PET/CT Can Predict Prognosis in Patients With Resectable Non-Small-Cell Lung Cancer.
Cancer Control
; 28: 10732748211038314, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34384268
10.
The Impact of EGFR Mutation Status and Brain Metastasis for Non-Small Cell Lung Cancer Treated with Ramucirumab plus Docetaxel.
Oncology
; 98(9): 661-668, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32464632
11.
Survival outcomes of adjuvant chemotherapy with modified weekly nab-paclitaxel and carboplatin for completely resected nonsmall cell lung cancer: FAST-nab.
Anticancer Drugs
; 31(2): 177-182, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31725045
12.
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.
Lancet Oncol
; 20(5): 625-635, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30975627
13.
Current status of clinical proteogenomics in lung cancer.
Expert Rev Proteomics
; 16(9): 761-772, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31402712
14.
Assessment of Bronchial Obstruction Using Lateral Pressure Measurement during Bronchoscopy.
Respiration
; 95(2): 106-113, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29190612
15.
Correction to: Osimertinib in poor performance status patients with T790Mpositive advanced nonsmallcell lung cancer after progression of first- and secondgeneration EGFRTKI treatments (NEJ032B).
Int J Clin Oncol
; 27(4): 823-824, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35257278
16.
Regional Lung Sound Asynchrony in Chronic Obstructive Pulmonary Disease Patients.
Respiration
; 92(4): 252-257, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27626282
17.
Cancer cell immunity-related protein co-expression networks are associated with early-stage solid-predominant lung adenocarcinoma.
Front Oncol
; 14: 1273780, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38450191
18.
A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study).
Eur J Cancer
; 197: 113469, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38061214
19.
A Phase â ¡ Study of Ubenimex Combined With Pembrolizumab, Nab-Paclitaxel, and Carboplatin for Previously Untreated Advanced Squamous Non-Small-Cell Lung Cancer: TORG2241 (UBE-Q).
Clin Lung Cancer
; 25(1): 85-90, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37981477
20.
Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non-small Cell Lung Cancer: TORG1937 (DATE Study).
Clin Cancer Res
; 30(6): 1104-1110, 2024 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38165684